Navigation Links
Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Date:12/10/2007

therapy.

Genta has filed a currently pending appeal to the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), which seeks reconsideration of FDA's decision in December 2006 not to approve the use of Genasense in patients with relapsed/refractory CLL.

"The addition of Genasense to chemotherapy has resulted in a clinically meaningful survival benefit for patients who achieved CR," commented Dr. O'Brien. "These data strongly confirm the high degree of clinical benefit that accrues to patients who achieve CR. Achievement of CR remains an essential goal of CLL treatment."

"As one of the patients who remains in CR more than 4 years after receiving Genasense on this study, I strongly support the pending appeal of FDA's decision that declined to make this drug available to other patients who suffer from CLL," commented Thomas F. Mahoney, who entered the Phase 3 Genasense trial in 2002.

Genasense in CLL

In the Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study - the only randomized controlled trial ever conducted in this population - achieved its intent-to-treat primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. In addition, the duration of CR - a prospectively specified and independent secondary endpoint -- was also significantly longer for patients treated with Genasense (median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for patients treated with chemotherapy alone).

The data presented today are exploratory analyses based on extended follow-up of all pat
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... DUBLIN, Ohio , Aug. 28, 2014 /PRNewswire/ ... rising competition in generics are adding pressure to ... internal resources. Company resources continue to shrink and ... complex. This has led companies to look for ... to commercialization and for keeping approved products on ...
(Date:8/28/2014)... , Aug. 28, 2014   RapidForce , ... announced today a strategic partnership with professional tennis player ... tennis player, Isner wears RapidForce during competitions to help ... competes this week at the 2014 US Open Tennis ... tape, RapidForce Physio Hybrid Shapes are a revolutionary hybrid ...
(Date:8/28/2014)... , Californie, 28 août 2014 ... annoncé aujourd,hui le début des inclusions ... étude  d,exemption des dispositifs expérimentaux (ou ... à évaluer l,innocuité et l,efficacité du ... Le docteur Adam Arthur , ...
Breaking Medicine Technology:4 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 2America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 3America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 4Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, today ... Services, and Chris Greco, Manager, Comparator and Ancillary ... Active Control Clinical Trials” at the forthcoming US ... the 9th – 10th September, 2014 in Philadelphia, ...
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
(Date:8/28/2014)... over who identify themselves as ,old, feel worse about ... have lower value than younger age groups. , New ... ,Being old and ill, across different countries: social status, ... from the European Social Survey. Respondents, who were all ... health., The researchers found that those living in societies ...
Breaking Medicine News(10 mins):Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Drug shows promise for subset of stage III colon cancer patients 2
... ALEXANDRIA, Va., July 23 The model for,person-centered long ... to testimony submitted today to the US Senate Special ... care that embraces choice,independence and the opportunity for seniors ... Richard Grimes, the President and CEO,of the Assisted Living ...
... had heart trouble, the worse their performance , , WEDNESDAY, July ... heart disease seem to fare worse on measures of cognitive ... disease, the worse the performance in such mental processes as ... the July 23 issue of the European Heart Journal ...
... Three years after Hurricane Katrina devastated parts of the Gulf ... Public Health Project on the Public and Biological Security shows ... they are very prepared if a major hurricane were to ... worries of respondents threatened or hit by Hurricane Katrina are ...
... Cohen Hired As New CEO, ATLANTA, July 23 ... MELCO Investments LLC, a private business and,real estate investment ... a,substantial capital investment in GMCG. Along with the investment, ... leading colon and rectal,surgeons, as its new CEO., ...
... and Medicare Rules Highlighted; a Focus on Preventing ... Hospital-acquired Conditions, LANSING, ... a national leader in clinical risk management,practice and patient safety programs ... for its annual risk,management conference., The conference will take place ...
... the #1 Healthiest City to,Live and Retire In -, ... voice for 50+ Americans and the world,s largest-circulation,magazine with ... ten,healthiest cities to live and retire in with Ann ... Fargo, ND taking the top five rankings.,Featured in the ...
Cached Medicine News:Health News:ASSISTED LIVING: The Model for Person-Centered Long Term Care 2Health News:Coronary Disease Dulls Cognitive Skills 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 3Health News:Hurricane preparedness survey: Worries about drinking water and medical care 4Health News:Hurricane preparedness survey: Worries about drinking water and medical care 5Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: